Related and Nonrelated Parties [Axis]
Nonrelated Party [Member]
Related Party [Member]
Product and Service [Axis]
Product [Member]
Service [Member]
License Royalty and Other [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Class of Stock [Axis]
Series A Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Concentration Risk Benchmark [Axis]
Accounts Receivable [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Customer [Axis]
Two Customers [Member]
Revenue Benchmark [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Restricted Stock Units (RSUs) [Member]
Market Condition Stock Units [Member]
Warrant [Member]
Convertible Debt Securities [Member]
Asset Acquisition [Axis]
Sequence LifeScience Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Nex Gel License Agreement [Member]
Nex Gel Inc. [Member]
Helena Global Investment Opportunities Ltd [Member]
Sequence Life Sciences Inc [Member]
Statistical Measurement [Axis]
Minimum [Member]
Short-Term Debt, Type [Axis]
December 2025 Promissory Note [Member]
December 2025 Convertible Note [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Lender Name [Axis]
Yorkville [Member]
Measurement Input Type [Axis]
Measurement Input Optional Redemption [Member]
Measurement Input Optional Redemption Upon Default [Member]
Measurement Input Default [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input Optional Conversion [Member]
Measurement Input Dissolution [Member]
Long-Lived Asset, Class [Axis]
Leasehold Improvements [Member]
Laboratory and Production Equipment [Member]
Machinery, Equipment and Fixtures [Member]
Segments [Axis]
Biobanking [Member]
Intangible Asset, Finite-Lived, Class [Axis]
Developed Technology Rights [Member]
Maximum [Member]
Customer Relationships [Member]
Trademarks and Trade Names [Member]
Reacquired Rights [Member]
Purchase Agreement [Member]
Title and Position [Axis]
Defeye Inc [Member]
Defeye License Agreement [Member]
Letter Agreement [Member]
Credit Facility [Axis]
2025 Convertible Note [Member]
2025 Promissory Note [Member]
CEO Promissory Note [Member]
Debt Instrument [Axis]
Office Manufacturing and Laboratory Space [Member]
Geographical [Axis]
Florham Park New Jersey [Member]
Business Combination [Axis]
Legacy Celularity [Member]
HLI Cellular Therapeutics LLC and Anthrogenesis [Member]
Legacy Celularitys [Member]
License Agreement [Member]
Litigation Case [Axis]
Evolution [Member]
Counterparty Name [Axis]
TCW Global [Member]
Target CW Global [Member]
Legal Entity [Axis]
Hackensack Meridian Health [Member]
Warrants [Member]
Common Class A [Member]
C.V. Starr Co Inc [Member]
March 2023 Loan Warrants [Member]
June 2023 Warrants [Member]
Class of Warrant or Right [Axis]
Award Type [Axis]
Employees [Member]
Market Condition Stock Unit [Member]
Plan Name [Axis]
2021 and 2017 Equity Incentive Plan [Member]
2021 Plan [Member]
2017 Plan [Member]
Location, Statement of Income, Balance [Axis]
Cell Therapy [Member]
Degenerative Disease [Member]
Other [Member]
Related Party Transaction [Axis]
Dr Robert Hariri [Member]
Securities Purchase Agreement [Member]
Loan Agreement [Member]
Lim Kok Thay [Member]
KTL Warrant [Member]
Senior Secured Loan Agreement [Member]
Asset Purchase Agreement [Member]
Technology Services Agreement [Member]
Asset Purchase and Exclusive License Agreement [Member]
Exclusive License Agreement [Member]
Defeye Letter Agreement [Member]
Defeye Series Seed-2 Preferred Stock [Member]
Manufacturing Collaboration with MuseCell Innovations Pte. Ltd [Member]
Chief Operating Officer [Member]
Senior Secured Convertible Notes [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Assets
Current assets:
Cash and cash equivalents
Accounts receivable, net of allowance of $7,847 and $7,647 as of March 31, 2026 and December 31, 2025, respectively
Inventory
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Goodwill
Intangible assets, net
Right-of-use assets - operating
Restricted cash
Inventory, net of current portion
Other long-term assets
Total assets
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Short-term debt
Short-term license obligation
Deferred revenue
Preferred stock redemption liability
Derivative liability
Total current liabilities
Deferred revenue, net of current portion
Noncurrent acquisition - related contingent consideration
Noncurrent lease liabilities - operating
Warrant liabilities
Long-term license obligation
Deferred income tax liabilities
Other liabilities
Total liabilities
Commitments and contingencies (Note 13)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 1,732,084 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Common Stock, $0.0001 par value, 730,000,000 shares authorized; 29,179,751 and 28,837,787 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ deficit
Total liabilities and stockholders’ deficit
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Statement [Table]
Statement [Line Items]
Net revenues
Total revenues
Operating expenses
Cost of revenues (excluding amortization of acquired intangible assets)
Cost of revenues
Research and development
Selling, general and administrative
Amortization of acquired intangible assets
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Change in fair value of warrant liabilities
Change in fair value of debt
Loss on debt extinguishment
Sale of New Jersey state tax loss benefits
Other expense, net
Total other income (expense)
Net income (loss)
Deemed dividend relating to inducement of Dragasac warrants
Earnings allocated to participating warrants
Net income (loss) attributable to common shareholders and participating warrants
Per share information:
Net income (loss) per share - basic
Weighted average shares outstanding - basic
Net income (loss) per share - diluted
Weighted average shares outstanding - diluted
Net income (loss)
Other comprehensive income (loss)
Change in fair value of debt due to change in credit risk, net of tax
Comprehensive income (loss)
Balance
Balance, shares
Vesting of restricted stock units
Vesting of restricted stock units, shares
Tax withholding on vesting of restricted stock units
Issuance to Dragasac in connection with warrant repricing
Issuance to Dragasac in connection with warrant repricing, shares
Dragasac Warrant Issuance Inducement
Issuance of common stock consideration shares to Yorkville in connection with Side Letter
Issuance of common stock consideration shares to Yorkville in connection with Side Letter, shares
Issuance of common stock in connection with settlement of debt
Issuance of common stock in connection with settlement of debt, shares
Issuance and modification of warrants to C. V. Starr
Change in FV of debt
Stock-based compensation expense
Net income (loss)
Issuance of warrants for Strategic Advisory Services
Issuance of common stock in connection with legal settlement
Issuance of common stock in connection with legal settlement, shares
Director fees paid with restricted stock units
Director fees paid with restricted stock units, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flow from operating activities:
Adjustments to reconcile net income (loss) to net cash provided by (used in) operations:
Depreciation and amortization
Non cash lease expense
Provision for inventory obsolescence
Provision for credit losses
Change in fair value of warrant liabilities
Issuance of warrants due to Strategic Advisory Agreement
Loss on issuance of common stock to Yorkville in connection with the Side Letter
Loss on issuance of common stock in connection with the settlement of debt
Share-based compensation expense
Director fees paid with RSU’s
Loss on extinguishment of debt
Change in fair value of debt
Non cash interest expense
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Lease liabilities
Deferred revenue
Net cash provided by (used in) operating activities
Cash flow from financing activities:
Issuance of common stock to Dragasac as consideration for inducement agreement
Repayments of short-term debt - unaffiliated
Payment of SEPA commitment fee
Repayments of other short-term debt - related party (R. Hariri)
Tax withholding on vesting of restricted stock units
Net cash (used in) provided by financing activities
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental non-cash investing and financing activities:
Contingent consideration accrued in connection with Rebound asset acquisition
Deemed dividend relating to inducement of Dragasac warrants
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
Business
Summary of Significant Accounting Policies
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Asset Purchases and Sales
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities
Inventory Disclosure [Abstract]
Inventory
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets
Property, Plant, and Equipment [Abstract]
Property and Equipment, Net
Intangible Asset, Goodwill and Other [Abstract]
Goodwill and Intangible Assets, Net
Investments, All Other Investments [Abstract]
Investments – Equity Securities
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Debt Disclosure [Abstract]
Debt
Lease Agreements
Lease Agreements
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Equity [Abstract]
Equity
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Revenue from Contract with Customer [Abstract]
Deferred Revenue
License And Distribution Agreements
License and Distribution Agreements
Retirement Benefits [Abstract]
Benefit Plan
Income Tax Disclosure [Abstract]
Income Taxes - Sale of Rights to Net Operating Loss Carryforwards
Segment Reporting [Abstract]
Segment Information
Related Party Transactions [Abstract]
Related Party Transactions
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Use of Estimates
Fair Value Measurements
Revenue Recognition
Concentrations of Credit Risk and Significant Customers and Allowance for Doubtful Accounts
Equity Method Investments
Net Income (Loss) per Share
Segment Information
Allowance for Credit Losses
Recently Issued Accounting Pronouncements
Schedule of Basic and Diluted Net Income (Loss) Per Share
Schedule of Potentially Dilutive Securities
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Schedule of Financial Assets and Liabilities Measures at Fair Value
Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis
Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis
Schedule of Convertible Note Valuation Model
Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis
Schedule of Major Classes of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property and Equipment, Net
Schedule of Carrying Value of Goodwill
Schedule of Intangible Assets, Net
Schedule of Aggregate Amortization Expense Related To Intangible Assets
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Debt
Schedule of Lease Costs
Schedule of Cash Activity Related to the lease Liabilities
Schedule of Future Minimum Payments under Operating Leases
Schedule of Weighted Average Grant Fair Value of Stock Options Using Black-Scholes Option-Pricing Model
Schedule of Stock Option Activity
Schedule of Activity Related to RSU Stock-Based Payment Awards
Schedule of Stock-based Compensation Expense
Schedule of Changes in Deferred Revenue from Contract Liabilities
Schedule of Financial Information by Segment
Subsequent Event [Table]
Subsequent Event [Line Items]
Net loss
Net cash used in operating activities
Net operating loss carryforwards
Accumulated deficit
Working capital deficit
Nasdaq market cap minimum
Bid price
Earnings allocated to participating warrants
Net income (loss) allocated to common shareholders
Weighted-average shares outstanding - basic
Effect of dilutive securities:
Stock options
Preferred stock
Weighted-average shares outstanding - diluted
Net income (loss) per share:
Basic
Diluted
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Concentration risk, percentage
Number of segments
Asset Acquisition [Table]
Asset Acquisition [Line Items]
Asset acquisition
Cash payment
Monthly milestone payments
Net sales percentage
Accured milestone payments
Net proceeds
Deferred payment
Pay sales commissions
Convertible note
Pay sales commissions
[custom:MilestonePayments]
[custom:FirstMilestonePayments]
Revenues
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration obligations
December 2025 Convertible Note
December 2025 Promissory Note
Warrant liability - July 2023 Registered Direct Warrants
Warrant liability - April 2023 Registered Direct Warrants
Warrant liability - May 2022 PIPE Warrants
Warrant liability - Public Warrants
Bifurcated embedded derivative - Series A Preferred Stock
Total fair value liabilities
Beginning balance
Net transfers in to (out of) Level 3
Purchases, settlements and other net
Fair value adjustments
Ending balance
Line of Credit Facility [Table]
Line of Credit Facility [Line Items]
Beginning balance
Repayment of December 2025 Promissory Note
Fair value adjustment through earnings
Ending balance
Issuance of unsecured senior convertible notes, net of fair value adjustment
Issuance of convertible promissory note
Conversion of debt into common shares
Conversion of debt into common shares
Fair value adjustment through accumulated other comprehensive income
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt, measurement input
Fair value of warrant liabilities, Beginning Balance
Loss recognized in earnings from change in fair value
Fair value of warrant liabilities, Ending Balance
Fair value of convertible note
Fair value of promissory note
Raw materials
Work in progress
Finished goods
Inventory, gross
Less: inventory reserves
Inventory, net
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid clinical expenses
Prepaid insurance expense
Other
Total
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property and equipment
Less: Accumulated depreciation and amortization
Property and equipment, net
Depreciation
Intangible Asset, Indefinite-Lived [Table]
Intangible Asset, Indefinite-Lived [Line Items]
Goodwill Balance
Goodwill Recognized
Goodwill Impairment
Goodwill Ending Balance
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Amortizable intangible assets
Estimated useful lives
Less: Accumulated amortization
Amortizable intangible assets, net
Acquired IPR&D product rights
Estimated useful lives
2026
2027
2028
2029
2030
Thereafter
Amortization expense
Goodwill impairments
Amortization expense for intangible assets
Impairment of intangible assets
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Company received shares
Product purchase credits
Preferred stock shares transferred back
Accrued clinical trial expense
Accrued professional fees
Accrued wages, bonuses, commissions, and vacation
Accrued compliance fee
Accrued vendor expenses
Royalty
Vendor settlements
Other
Total
Short-term debt – related parties
Total debt
Long-term debt – related parties
Total debt
Fair value of the debt
Principal amount
Repaid amount
Schedule Of Lease Costs
Operating lease cost
Variable lease cost
Total operating lease cost
Schedule Of Cash Activity Related To Lease Liabilities
Operating cash flows from operating leases
2026 (remaining 9 months)
2027
2028
2029
2030
Thereafter
Total lease payments
Less imputed interest
Total
Rent expense
[custom:AreaOfBuilding]
[custom:OperatingLeaseExpiryYear]
Lessee, Operating Lease, Option to Extend
Reduction in line of credit
New line of credit
Base rental payments
Weighted average remaining lease term
Weighted average discount rate
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Contingent consideration
Upfront fee
Annual maintenance fee
Clinical and regulatory milestones
License agreement period
Sale of biomaterial products amount
Litigation Settlement, Amount Awarded to Other Party
Affiliate Costs
Litigation Settlement, Amount Awarded from Other Party
Payments for Legal Settlements
[custom:RestrictedStockIssuedForLegalSettlement]
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt Instrument, Face Amount
Debt Instrument, Unamortized Discount
Warrants to purchase aggregate shares
Warrants per share
Class of Warrant or Right, Outstanding
Warrants and Rights Outstanding, Maturity Date
Loss on debt extinguishment
Debt Instrument, Maturity Date
Repayments of Other Debt
Risk-free interest rate
Expected term (in years)
Expected volatility
Expected dividend yield
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options beginning balance
Weighted Average Exercise Price, beginning balance
Options Granted
Weighted Average Exercise Price, Granted
Options Exercised
Weighted Average Exercise Price, Exercised
Options Forfeited
Weighted Average Exercise Price, Forfeited
Options ending balance
Weighted Average Exercise Price, ending balance
Weighted Average Contract Term
Aggregate Intrinsic Value
Options Vested and expected to vest
Weighted Average Exercise Price, Vested and expected to vest
Weighted Average Contract Term Vested and expected to vest
Aggregate Intrinsic Value Vested and expected to vest
Options Exercisable
Weighted Average Exercise Price, Exercisable
Weighted Average Contract Term Exercisable
Aggregate Intrinsic Value Exercisable
Options outstanding
Options outstanding including awards
Number of Shares, Outstanding beginning balance
Weighted Average Grant Date Fair Value,Outstanding beginning balance
Number of Shares, Granted
Weighted Average Grant Date Fair Value, Granted
Number of Shares, Vested
Weighted Average Grant Date Fair Value, Vested
Number of Shares, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Number of Shares, Outstanding ending balance
Weighted Average Grant Date Fair Value, Outstanding ending balance
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense
Weighted average grant-date fair value of stock options granted
Stock based compensation expense
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Estimated weighted-average amortization period
Restricted stock units vested
Tax withholding obligations
Shares issued to employees
Unrecognized compensation cost
Number of shares granted
Number of shares forfeited
Outstanding shares
Beginning balance
Deferral of revenue
Revenue recognized
Ending balance
Deferred revenue current
Contributions made to the plan
Proceeds from sale of net operating loss carryforwards
Segment Reporting [Table]
Segment Reporting [Line Items]
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses
Segment contribution
Indirect expenses
Loss from operations
Other income (expenses)
Loss before income taxes
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Base salary
Proceeds from equity securities
Bonus percentage
Reduction in base salary percentage
Debt principal amount
Loan interest rate
Loan principal and accrued interest
Interest rate
Warrant to purchase shares
Exercise price
Warrants term
Debt instrument, discount
Default interest rate
Accrued interest
Accrued paid-in kind interest
Royalty price percentage
Royalty expense
Licensing obligation
Licensing obligation premium
Revenue
Accounts receivable
Initial milestone payment
Additional milestone payment
Asset Acquisition, Price of Acquisition, Expected
Milestone payments
Outstanding principal percentage
Accrues interest rate percentage
Monthly cash installment payments
Cash paid for settlement
Subsequent event description
[custom:DeferredRevenueDefinedDiscount-0]
Shares returned
Voting interest, percentage
Minimum market value of listed securities
Purchase obligation
Cash proceeds from related party debt
Gross proceeds
Short-term license obligation.
Warrant liabilities.
Long-term license obligation.
Sequence LifeScience Inc [Member]
Monthly milestone payments.
Change in fair value of debt.
Deemed dividend relating to inducement of warrants.
Change In fair value of debt due to change in credit risk net of tax.
License Royalty and Other [Member]
Outstanding principal percentage
Net sales percentage.
Accured milestone payments.
Accrues interest rate percentage
Biobanking [Member]
Target CW Global [Member]
Schedule of Intangible Assets Net [Table Text Block]
Reacquired Rights [Member]
Warrants [Member]
C.V. Starr Co Inc [Member]
Indefinite lived intangible assets amortization method.
Floor price.
March 2023 Loan Warrants [Member]
June 2023 Warrants [Member]
2021 and 2017 Equity Incentive Plan [Member]
2021 Plan [Member]
2017 Plan [Member]
Nex Gel Inc. [Member]
Nex Gel License Agreement [Member]
Purchase Agreement [Member]
Defeye Inc [Member]
Stock issued during period value issuance of common stock consideration shares to in connection with side letter.
Stock issued during period shares issuance of common stock consideration shares to in connection with side letter.
Stock issued during period value issuance of common stock in connection with settlement of debt.
Stock issued during period shares issuance of common stock in connection with settlement of debt.
Adjustments to additional paid in capital issuance and modification of warrants.
Milestone payments.
Contract with customer liability increase decrease for contract from business combination and deferred revenue.
First milestone payments.
Letter Agreement [Member]
Defeye License Agreement [Member]
Adjustments to additional paid in capital issuance of warrants for strategic advisory services.
Value of shares of stock issued during the period director fees paid with restricted stock units.
Number of shares of stock issued during the period vesting of restricted stock units
Accrued clinical trial expense.
Accrued compliance fee.
Accrued vendor expenses.
Proceeds from sale of net operating loss carryforwards.
Accrued vendor settlements
Short-term debt - related parties.
Non cash lease expense.
Loss on issuance of common stock to in connection with side letter.
Issuance of common stock in connection with settlement of debt.
Non cash interest expense.
Payment of sepa commitment fee.
Deemed dividend relating to inducement of Dragasac warrants.
Debt.
License and Distribution Agreements [Text Block]
Cell Therapy [Member]
Degenerative Disease [Member]
Other [Member]
Segment contribution.
Indirect expenses.
Issuance of warrants for strategic advisory agreement.
2025 Convertible Note [Member]
2025 Promissory Note [Member]
CEO Promissory Note [Member]
December 2025 Convertible Note [Member]
Warrant liability registered direct warrants two.
Warrant liability registered direct warrants.
Warrant liability private investment in public equity warrants.
Warrant liability public warrants.
Contingent consideration accrued in connection with Rebound asset acquisition.
December 2025 Promissory Note [Member]
Working capital deficit.
Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]
HLI Cellular Therapeutics LLC and Anthrogenesis [Member]
Legacy Celularitys [Member]
Clinical and regulatory milestones.
License Agreement [Member]
Upfront fee.
Annual maintenance fee.
Yorkville [Member]
License agreement notice period.
Issuance of convertible notes net of fair value adjustment.
Fair value measurement with unobservable inputs reconciliation convertible promissory note.
Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares.
Fair value measurement with unobservable inputs reconciliation settlement of debt in connection with issuance of common stock.
Fair value adjustment through earnings.
Fair value adjustment through accumulated other comprehensive income.
Two Customers [Member]
Sale of biomaterial products amount.
Evolution [Member]
TCW Global [Member]
Recently Adopted Accounting Pronouncements [Policy Text Block]
Disclosure of accounting policy related to allowance for credit losses.
Measurement Input Optional Redemption [Member]
Measurement Input Optional Redemption Upon Default [Member]
Measurement Input Default [Member]
Measurement Input Optional Conversion [Member]
Market Condition Stock Units [Member]
Measurement Input Dissolution [Member]
Gain loss recognized in earnings from change in fair values.
Schedule Of Inventory Current And Noncurrent [Table Text Block]
Hackensack Meridian Health [Member]
Inventory raw materials current and noncurrent.
Inventory work in progress current and noncurrent.
Inventory finished goods current and noncurrent.
Inventory gross current and noncurrent.
Inventory reserve current and noncurrent.
Inventory net current and noncurrent.
Prepaid Expenses And Other Current Assets Disclosure [Text Block]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]
Prepaid clinical expense.
Unpaid base salary.
Dr Robert Hariri [Member]
Securities Purchase Agreement [Member]
Percentage of base salary.
Annual rate of base salary.
Percentage of unpaid base salary.
Loan Agreement [Member]
Lim Kok Thay [Member]
KTL Warrant [Member]
Senior Secured Loan Agreement [Member]
Asset Purchase Agreement [Member]
Royalty price percentage.
Licensing obligation.
License obligation premium.
Technology Services Agreement [Member]
Asset Purchase and Exclusive License Agreement [Member]
The amount of consideration recognized during the period for the initial milestone or milestones.
The amount of consideration recognized during the period for the additional milestone or milestones.
Defeye Letter Agreement [Member]
Deferred revenue defined discount.
Defeye Series Seed-2 Preferred Stock [Member]
Minimum market value of listed securities.
Manufacturing Collaboration with MuseCell Innovations Pte. Ltd [Member]
Laboratory and Production Equipment [Member]
Machinery, Equipment and Fixtures [Member]
Operating income costs and expenses.
Sale of New Jersey state tax loss benefits.
Payment One [Member]
Payment Two [Member]
Nasdaq market cap minimum.
Product purchase credits.
Preferred stock shares transferred back.
The aggregate amount of principal and accrued interest related to the loans.
Cash payments from monthly cash installment payments.
Cash paid for settlement.
Preferred stock voting interest percentage.
Restricted stock issued for legal settlement.
Nexgel Agreement [Member]
Upfront cash payment.
Convertible Promissory Note [Member]
First milestone payment.
Net sales threshold for milestone payment.
Milestone payment period.
Minimum net sales for milestone payment.
Proceeds from license agreement.
Operating leases rent expense.
Area of building.
Office Manufacturing and Laboratory Space [Member]
Florham Park New Jersey [Member]
Legacy Celularity [Member]
Operating lease expiry year.
Operating lease commencement date.
Initial monthly base rent.
Reduction in line of credit.
New line of credit.
Base rental payments.
Cash and Non Cash Activity Related To Lease Liabilities [Table Text Block]
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Market Condition Stock Unit [Member]
Exclusive License Agreement [Member]
Senior Secured Convertible Notes [Member]
Earnings allocated to participating warrants.
Tax withholding obligations.
Employees [Member]
Payment of bonus percentage.
Reduction in base salary percentage.
Net income loss attributable to common stock.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
OperatingIncomeCostsAndExpenses
Operating Income (Loss)
Interest Expense, Nonoperating
DeemedDividendRelatingToInducementOfWarrants
EarningsAllocatedToParticipatingWarrants
Net Income (Loss) Available to Common Stockholders, Basic
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Contract with Customer, Liability
Repayments of Short-Term Debt
PaymentOfSepaCommitmentFee
Payment, Tax Withholding, Share-Based Payment Arrangement
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Inventory Disclosure [Text Block]
Lessee, Operating Leases [Text Block]
Segment Reporting, Policy [Policy Text Block]
WorkingCapitalDeficit
Convertible Debt
Liabilities, Fair Value Disclosure
Receivables, Fair Value Disclosure
Repayments of Notes Payable
FairValueMeasurementWithUnobservableInputsReconciliationSettlementOfDebtInConnectionWithIssuanceOfCommonStock
Fair Value, Net Asset (Liability)
InventoryGrossCurrentAndNoncurrent
InventoryReserveCurrentAndNoncurrent
InventoryNetCurrentAndNoncurrent
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
IndefiniteLivedIntangibleAssetsAmortizationMethod
Other Accrued Liabilities, Current
Accrued Liabilities, Current
Debt [Default Label]
Lease, Cost
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Extinguishment of Debt, Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Contract with Customer, Liability